Evaluation and design

The aim of this communication is to describe how aiding-design tools can evaluate designed solutions to help users make the best choices, avoid design mistakes and reduce the design time-cycle. Fir...

[1]  Mark Dybul,et al.  Guidelines for Using Antiretroviral Agents among HIV-Infected Adults and Adolescents: The Panel on Clinical Practices for Treatment of HIV* , 2002, Annals of Internal Medicine.

[2]  B. Marchand,et al.  Mutations E44D and V118I in the Reverse Transcriptase of HIV-1 Play Distinct Mechanistic Roles in Dual Resistance to AZT and 3TC* , 2003, Journal of Biological Chemistry.

[3]  S. Hammer,et al.  Antiretroviral drug resistance testing in adult HIV-1 infection: recommendations of an International AIDS Society-USA Panel. , 2000, JAMA.

[4]  D. Katzenstein,et al.  Combination therapy with zidovudine and didanosine selects for drug-resistant human immunodeficiency virus type 1 strains with unique patterns of pol gene mutations. , 1994, The Journal of infectious diseases.

[5]  J. Esparza,et al.  Proposed 'World Health Organization Staging System for HIV Infection and Disease': preliminary testing by an international collaborative cross‐sectional study , 1993, AIDS.

[6]  L. Guay,et al.  Performance of Applied Biosystems ViroSeq HIV-1 Genotyping System for Sequence-Based Analysis of Non-Subtype B Human Immunodeficiency Virus Type 1 from Uganda , 2001, Journal of Clinical Microbiology.

[7]  L. Mofenson,et al.  Identification of the K103N resistance mutation in Ugandan women receiving nevirapine to prevent HIV-1 vertical transmission , 2000, AIDS.

[8]  Virginia Litwin,et al.  HIV-1 entry into CD4+ cells is mediated by the chemokine receptor CC-CKR-5 , 1996, Nature.

[9]  M. H. Schultz,et al.  Topological properties of hypercubes , 1988, IEEE Trans. Computers.

[10]  D. Stammers,et al.  Closing in on HIV drug resistance , 1999, Nature Structural Biology.

[11]  Y. Cao,et al.  HIV-1 drug resistance in newly infected individuals. , 1999, JAMA.

[12]  D. Trono,et al.  Hide, shield and strike back: how HIV-infected cells avoid immune eradication , 2003, Nature Reviews Immunology.

[13]  F. Baldanti,et al.  Nevirapine-selected mutations Y181I/C of HIV-1 reverse transcriptase confer cross-resistance to stavudine , 2003, AIDS.

[14]  Anthony S Fauci,et al.  HIV and AIDS: 20 years of science , 2003, Nature Medicine.

[15]  S. Hammer,et al.  Phenotypic and genotypic resistance patterns of HIV-1 isolates derived from individuals treated with didanosine and stavudine , 2000, AIDS.

[16]  S. Cassol,et al.  Molecular Characteristics of Human Immunodeficiency Virus Type 1 Subtype C Viruses from KwaZulu-Natal, South Africa: Implications for Vaccine and Antiretroviral Control Strategies , 2003, Journal of Virology.

[17]  F. Brun-Vézinet,et al.  Susceptibility of human immunodeficiency virus type 1 group O isolates to antiretroviral agents: in vitro phenotypic and genotypic analyses , 1997, Journal of virology.

[18]  M. Re,et al.  Analysis of HIV-1 drug resistant mutations by line probe assay and direct sequencing in a cohort of therapy naive HIV-1 infected Italian patients , 2001, BMC Microbiology.

[19]  C. Brennan,et al.  Performance of the Celera Diagnostics ViroSeq HIV-1 Genotyping System for Sequence-Based Analysis of Diverse Human Immunodeficiency Virus Type 1 Strains , 2004, Journal of Clinical Microbiology.

[20]  M. Greaves,et al.  The CD4 (T4) antigen is an essential component of the receptor for the AIDS retrovirus , 1984, Nature.

[21]  A. D. Clark,et al.  The Lys103Asn mutation of HIV-1 RT: a novel mechanism of drug resistance. , 2001, Journal of molecular biology.

[22]  G. Pauli,et al.  Morphogenesis and morphology of HIV structure-function relations , 2005, Archives of Virology.

[23]  K. Gunther,et al.  Prevention of Deadlocks in Packet-Switched Data Transport Systems , 1981 .

[24]  R. Pomerantz,et al.  Twenty years of therapy for HIV-1 infection , 2003, Nature Medicine.

[25]  Ingrid A. Beck,et al.  Rapid and Sensitive Oligonucleotide Ligation Assay for Detection of Mutations in Human Immunodeficiency Virus Type 1 Associated with High-Level Resistance to Protease Inhibitors , 2002, Journal of Clinical Microbiology.

[26]  T. Steitz,et al.  Crystal structure at 3.5 A resolution of HIV-1 reverse transcriptase complexed with an inhibitor. , 1992, Science.

[27]  A. Antinori,et al.  Usefulness of monitoring HIV drug resistance and adherence in individuals failing highly active antiretroviral therapy: a randomized study (ARGENTA) , 2002, AIDS.

[28]  H. Fleury,et al.  Emergence of zidovudine and multidrug-resistance mutations in the HIV-1 reverse transcriptase gene in therapy-naive patients receiving stavudine plus didanosine combination therapy. STADI Group. , 1999, AIDS.

[29]  A. Sönnerborg,et al.  Use of HIV-1 reverse transcriptase recovered from human plasma for phenotypic drug susceptibility testing , 2003, AIDS.

[30]  P. Boyer,et al.  Mutational analysis of the fingers domain of human immunodeficiency virus type 1 reverse transcriptase , 1992, Journal of virology.

[31]  S. King.  HIV: virology and mechanisms of disease. , 1994, Annals of emergency medicine.

[32]  J. Chermann,et al.  IMMUNE STATUS OF AIDS PATIENTS IN FRANCE: RELATIONSHIP WITH LYMPHADENOPATHY ASSOCIATED VIRUS TROPISM a , 1984, Annals of the New York Academy of Sciences.

[33]  R. Shafer,et al.  Drug resistance mutations in HIV-1. , 2003, Topics in HIV medicine : a publication of the International AIDS Society, USA.

[34]  L. Morris,et al.  Low frequency of the V106M mutation among HIV-1 subtype C-infected pregnant women exposed to nevirapine , 2003, AIDS.

[35]  William J. Dally,et al.  Deadlock-Free Message Routing in Multiprocessor Interconnection Networks , 1987, IEEE Transactions on Computers.

[36]  D. Nickerson,et al.  Oligonucleotide Ligation Assay for Detecting Mutations in the Human Immunodeficiency Virus Type 1 polGene That Are Associated with Resistance to Zidovudine, Didanosine, and Lamivudine , 1998, Journal of Clinical Microbiology.

[37]  B. Larder,et al.  Ordered appearance of zidovudine resistance mutations during treatment of 18 human immunodeficiency virus-positive subjects. , 1992, The Journal of infectious diseases.

[38]  C. Broder,et al.  CC CKR5: A RANTES, MIP-1α, MIP-1ॆ Receptor as a Fusion Cofactor for Macrophage-Tropic HIV-1 , 1996, Science.

[39]  D. Pillay,et al.  Resistance-Associated Mutations in the Human Immunodeficiency Virus Type 1 Subtype C Protease Gene from Treated and Untreated Patients in the United Kingdom , 2001, Journal of Clinical Microbiology.

[40]  M. Summers,et al.  Structural biology of HIV. , 1999, Journal of molecular biology.

[41]  T. Merigan,et al.  A randomized study of antiretroviral management based on plasma genotypic antiretroviral resistance testing in patients failing therapy , 2000 .

[42]  T. Tucker,et al.  Laboratory monitoring of HIV--after access to antiretroviral drugs, the next challenge for the developing world. , 2001, South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde.

[43]  E. De Clercq,et al.  Comparison of the LiPA HIV-1 RT test, selective PCR and direct solid phase sequencing for the detection of HIV-1 drug resistance mutations. , 1998, Journal of virological methods.

[44]  G L Verdine,et al.  Structure of a covalently trapped catalytic complex of HIV-1 reverse transcriptase: implications for drug resistance. , 1998, Science.

[45]  M. Moroni,et al.  Impact of Mutations Conferring Reduced Susceptibility to Lamivudine on the Response to Antiretroviral Therapy , 2000, Antiviral therapy.

[46]  S. Hammer,et al.  The Relation between Baseline HIV Drug Resistance and Response to Antiretroviral Therapy: Re-Analysis of Retrospective and Prospective Studies Using a Standardized Data Analysis Plan , 2000, Antiviral therapy.

[47]  C. Leport,et al.  Amprenavir Inhibitory Quotient and Virological Response in Human Immunodeficiency Virus-Infected Patients on an Amprenavir-Containing Salvage Regimen without or with Ritonavir , 2002, Antimicrobial Agents and Chemotherapy.

[48]  L. Morris,et al.  HIV-1 subtype C reverse transcriptase sequences from drug-naive pregnant women in South Africa. , 2002, AIDS research and human retroviruses.

[49]  S. Lazzari,et al.  HIV Drug Resistance Surveillance: Summary of an April 2003 WHO Consultation , 2004, AIDS.

[50]  J. Coffin,et al.  HIV population dynamics in vivo: implications for genetic variation, pathogenesis, and therapy , 1995, Science.

[51]  T. Matthews,et al.  Peptides corresponding to a predictive alpha-helical domain of human immunodeficiency virus type 1 gp41 are potent inhibitors of virus infection. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[52]  L. M. Mansky,et al.  Retrovirus mutation rates and their role in genetic variation. , 1998, The Journal of general virology.

[53]  S. Yerly,et al.  Transmission of antiretroviral-drug-resistant HIV-1 variants , 1999, The Lancet.